ELI LILLY AND COMPANY Deferred Tax Assets, Other Comprehensive Loss
ELI LILLY AND COMPANY (LLY) had Deferred Tax Assets, Other Comprehensive Loss of $59.60 million as of 2019-12-31, per its 10-K filed 2020-02-19.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOtherComprehensiveLoss · last filed 2020-02-19
- 2019-12-31: Deferred Tax Assets, Other Comprehensive Loss $59.60M.
- 2018-12-31: Deferred Tax Assets, Other Comprehensive Loss $68.90M.
- 2017-12-31: Deferred Tax Assets, Other Comprehensive Loss $68.90M.
- 2016-12-31: Deferred Tax Assets, Other Comprehensive Loss $123.30M.
| Period end | Deferred Tax Assets, Other Comprehensive Loss |
|---|---|
| 2019-12-31 | $59.60M 10-K · filed 2020-02-19 |
| 2018-12-31 | $68.90M 10-K · filed 2020-02-19 |
| 2017-12-31 | $68.90M 8-K · filed 2019-10-24 |
| 2016-12-31 | $123.30M 10-K · filed 2018-02-20 |
| 2015-12-31 | $129.70M 10-K · filed 2017-02-21 |
| 2014-12-31 | $115.30M 10-K · filed 2016-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |